QuidelOrtho Sells Testing Unit for $1.5B to Focus on Core Lab
1h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
quidelorthomedical-devices
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
QuidelOrtho Corporation is selling its testing unit for $1.5 billion in a major strategic divestiture, the company announced on June 27, 2026. The planned sale aims to strengthen the company's focus on its core clinical laboratory and transfusion medicine businesses. This move follows a challenging fiscal 2025 that saw QuidelOrtho post a net loss of $2.8 billion against total revenue of $3.2 billion. The transaction proceeds are earmarked for debt reduction and strategic reinvestment.
The planned divestiture occurs at a pivotal moment for QuidelOrtho, formed through the $6 billion merger of Quidel Corporation and Ortho Clinical Diagnostics in 2022. That merger aimed to create a comprehensive diagnostics leader but was followed by significant integration challenges and market headwinds. The broader diagnostics sector faces persistent pricing pressure and normalized demand post-pandemic, with the S&P 500 Health Care Equipment Index underperforming the broader S&P 500 by 400 basis points year-to-date. The sale represents a decisive reversal from the conglomerate strategy, triggered by activist investor pressure and the need to improve operational efficiency and shareholder returns after consecutive quarters of financial underperformance.
The last comparable major divestiture in the diagnostics space was Siemens Healthineers' sale of its hearing aid division to EQT for $5.6 billion in 2024. That deal allowed Siemens to sharpen its focus on imaging and advanced therapies, a precedent QuidelOrtho appears to be following. The current macro backdrop of elevated borrowing costs, with the 10-year Treasury yield stabilizing near 4.2%, makes deleveraging a priority for capital-intensive healthcare firms. The catalyst for action now is the looming maturity wall of debt taken on during the 2022 merger and the necessity to demonstrate a credible turnaround path to the market.
The $1.5 billion sale price represents a significant valuation for the non-core testing assets. The unit contributed approximately $700 million in annual revenue, implying a revenue multiple of 2.1x. QuidelOrtho's total company enterprise value prior to the announcement was approximately $4.8 billion. Management projects the divestiture will generate annualized cost savings of $85 million, primarily from reduced SG&A expenses. The company's net debt stood at $3.1 billion as of its last quarterly filing, a figure the sale will materially reduce.
A before-and-after comparison illustrates the strategic shift. Before the sale, the testing unit comprised roughly 22% of QuidelOrtho's total revenue. After the sale, the company's revenue profile will be concentrated in higher-margin clinical lab and blood screening segments. The company's consolidated operating margin, which was negative 15% in 2025, is projected to improve by 250-300 basis points post-divestiture. This compares to peer Danaher Corporation's Diagnostics segment, which maintains operating margins above 25%. The transaction is expected to close by the end of 2026, pending regulatory approvals.
| Metric | Pre-Sale (2025) | Pro Forma Post-Sale (Projected) |
|---|---|---|
| Total Revenue | $3.2 billion | ~$2.5 billion |
| Net Debt | $3.1 billion | ~$1.6 billion |
| Annual Cost Base | Baseline | -$85 million |
The immediate beneficiary is QuidelOrtho's balance sheet, with leverage ratios expected to improve markedly. The stock (QDEL) may see support from value-focused investors attracted to a simpler, less indebted story. Second-order gains could flow to pure-play point-of-care testing competitors like Abbott Laboratories (ABT) and Becton, Dickinson and Company (BDX), which may capture market share from the divested unit. Diagnostic service providers like Laboratory Corporation of America (LH) and Quest Diagnostics (DGX) could benefit from a more focused QuidelOrtho as a supplier.
A counter-argument is that the sale shrinks the company's scale and diversifies its revenue, potentially making it more vulnerable to cyclical swings in its remaining lab-focused markets. The $1.5 billion price tag, while substantial, may be viewed as a discount if the unit's growth prospects were stronger than communicated. Positioning data shows short interest in QDEL had climbed to 12% of float ahead of the announcement, suggesting skepticism. Post-announcement, flow is likely towards covering short positions and establishing long positions by event-driven and special situation funds betting on successful execution.
The primary catalyst is the formal closure of the transaction, expected by Q4 2026. Investor focus will shift to QuidelOrtho's Q2 2026 earnings call, scheduled for late July, where management will detail the use of proceeds and provide updated full-year guidance excluding the testing unit. Regulatory scrutiny, particularly from the Federal Trade Commission regarding market concentration in specific test segments, remains a watchpoint.
Key levels to monitor include QDEL's share price holding above its 50-day moving average, currently near $48, as a sign of sustained positive sentiment. The success of the strategic pivot will be measured by the company's ability to return its core lab business to mid-single-digit organic growth, a threshold it has not met since the merger. Bond markets will watch for a ratings outlook change from agencies like Moody's, currently holding a Ba3 corporate family rating with a negative outlook, following the debt paydown.
Retail investors in QDEL now own a more focused, less leveraged company. The $1.5 billion inflow reduces bankruptcy risk and interest expense, potentially leading to more stable earnings. However, the company is also smaller, with pro forma revenue dropping to around $2.5 billion, which may limit its competitive clout against giants like Roche and Abbott. The investment thesis shifts from a broad diagnostics play to a bet on execution in specific lab and transfusion niches.
The move follows a common pattern of post-merger simplification. Similar to Zimmer Biomet's sale of its dental unit in 2022 for $1.2 billion, QuidelOrtho is shedding a non-core, lower-margin business to shore up the balance sheet after a large merger. The key difference is the magnitude of financial distress preceding the sale; QuidelOrtho's $2.8 billion loss in 2025 created more urgent pressure to act compared to Zimmer's strategic portfolio pruning during stable profitability.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.